Cardio Diagnostics (NASDAQ:CDIO) Releases Quarterly Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) released its earnings results on Friday. The company reported ($0.59) EPS for the quarter, Zacks reports. Cardio Diagnostics had a negative return on equity of 82.28% and a negative net margin of 43,133.33%.

Cardio Diagnostics Price Performance

Shares of NASDAQ CDIO remained flat at $1.68 during mid-day trading on Friday. The stock had a trading volume of 18,908 shares, compared to its average volume of 23,643. Cardio Diagnostics has a twelve month low of $0.97 and a twelve month high of $7.91. The business’s 50-day moving average is $1.84 and its 200 day moving average is $2.06. The firm has a market cap of $4.96 million, a PE ratio of -0.57 and a beta of 2.32.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cardio Diagnostics in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has an average rating of “Sell”.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care.

The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.